Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	O
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	O
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
May	O
29	O
,	O
2020	O
May	O
29	O
,	O
2020	O
MDSotaroSadahiro	B-authors

143	O
Shimokasuya	O
Isehara	O
259	O
-	O
1193	O
Japan	O
ToshiyukiSuzuki	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
KazutakeOkada	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
GotaSaito	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
HiroshiMiyakita	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
TakashiOgimi	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
LinFungChan	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
YutaroKamei	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O

Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	B-arm_description
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	B-study_type
II	I-study_type
Trial	I-study_type

Received	O
:	O
February	O
18	O
,	O
2020	O
Accepted	O
:	O
March	O
16	O
,	O
2020	O
MDSotaroSadahiro	B-authors
sadahiro@is.icc.u-tokai.ac.jp	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O

143	O
Shimokasuya	O
Isehara	O
259	O
-	O
1193	O
Japan	O
ToshiyukiSuzuki	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
KazutakeOkada	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
GotaSaito	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
HiroshiMiyakita	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
TakashiOgimi	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
LinFungChan	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
YutaroKamei	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O

Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	B-arm_description
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	B-study_type
II	I-study_type
Trial	I-study_type

Received	O
:	O
February	O
18	O
,	O
2020	O
Accepted	O
:	O
March	O
16	O
,	O
2020	O
MDSotaroSadahiro	B-authors
sadahiro@is.icc.u-tokai.ac.jp	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O

143	O
Shimokasuya	O
Isehara	O
259	O
-	O
1193	O
Japan	O
ToshiyukiSuzuki	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
KazutakeOkada	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
GotaSaito	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
HiroshiMiyakita	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
TakashiOgimi	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
LinFungChan	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
YutaroKamei	B-authors
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O

Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	B-arm_description
plus	O
Bevacizumab	B-arm_description
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	B-arm_description
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
MDSotaroSadahiro	B-authors
sadahiro@is.icc.u-tokai.ac.jp	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O
Isehara	O
Japan	O
Department	O
of	O
Surgery	O
School	O
of	O
Medicine	O
Tokai	O
University	O

Japan	O
Isehara	O
Japan	O
Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	B-arm_description
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	B-arm_description
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
May	O
29	O
,	O
2020	O
May	O
29	O
,	O
2020	O
May	O
29	O
,	O
2020	O
10.1159/000507293	O
Received	O
:	O
February	O
18	O
,	O
2020	O
Accepted	O
:	O
March	O
16	O
,	O
2020	O

Fluorouracil	O
(	O
FU)-based	O
doublets	O
,	O
including	O
oxaliplatin	O
or	O
irinotecan	O
,	O
plus	O
bevacizumab	O
have	O
been	O
widely	O
used	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
colorectal	O
cancer	O
(	O
mCRC	O
)	O
[	O
1][2][3	O
]	O
.	O
Combination	O
regimens	O
of	O
FU	O
and	O
ox-	O
Sadahiro	O
aliplatin	O
,	O
such	O
as	O
FOLFOX	O
,	O
CapeOx	O
,	O
and	O
SOX	O
(	O
S-1	O
plus	O
oxaliplatin	O
)	O
,	O
are	O
more	O
commonly	O
used	O
in	O
clinical	O
practice	O
than	O
combination	O
regimens	O
of	O
FU	O
and	O
irinotecan	O
,	O
such	O
as	O
FOLFIRI	O
.	O
However	O
,	O
peripheral	O
neuropathy	O
associated	O
with	O
oxaliplatin	O
often	O
leads	O
to	O
early	O
treatment	O
withdrawal	O
and	O
negatively	O
affects	O
treatment	O
continuity	O
.	O
Prolonged	O
peripheral	O
neuropathy	O
affects	O
patients	O
'	O
daily	O
life	O
activities	O
and	O
their	O
quality	O
of	O
life	O
[	O
4,5	O
]	O
.	O
In	O
contrast	O
,	O
the	O
combination	O
regimens	O
of	O
FU	O
and	O
irinotecan	O
can	O
be	O
continued	O
for	O
long	O
periods	O
in	O
many	O
patients	O
by	O
managing	O
early	O
major	O
toxicity	O
such	O
as	O
diarrhea	O
.	O

Irinotecan	O
is	O
usually	O
given	O
as	O
a	O
90-min	O
intravenous	O
infusion	O
biweekly	O
or	O
triweekly	O
.	O
However	O
,	O
the	O
cytotoxic	O
effects	O
of	O
irinotecan	O
are	O
specific	O
to	O
the	O
S	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
low	O
doses	O
of	O
irinotecan	O
given	O
by	O
protracted	O
infusion	O
or	O
frequent	O
bolus	O
injection	O
can	O
prevent	O
the	O
saturation	O
of	O
carboxylesterases	O
,	O
enzymes	O
that	O
convert	O
irinotecan	O
to	O
its	O
active	O
metabolite	O
SN-38	O
,	O
and	O
thereby	O
enhance	O
antitumor	O
activity	O
[	O
6,7	O
]	O
.	O
We	O
have	O
previously	O
performed	O
several	O
clinical	O
trials	O
of	O
a	O
24-h	O
continuous	O
intravenous	O
infusion	O
of	O
irinotecan	O
,	O
given	O
biweekly	O
,	O
combined	O
with	O
oral	O
FUs	O
(	O
UFT	O
and	O
UFT	O
plus	O
leucovorin	O
)	O
,	O
in	O
patients	O
with	O
mCRC	O
and	O
reported	O
that	O
these	O
regimens	O
are	O
therapeutically	O
useful	O
and	O
have	O
low	O
incidences	O
of	O
diarrhea	O
and	O
other	O
adverse	O
events	O
[	O
8,9	O
]	O
.	O
To	O
date	O
,	O
however	O
,	O
no	O
randomized	O
clinical	O
trial	O
has	O
compared	O
a	O
24-h	O
continuous	O
infusion	O
of	O
irinotecan	O
with	O
a	O
standard	O
90-min	O
infusion	O
of	O
irinotecan	O
.	O

S-1	O
is	O
an	O
oral	O
anticancer	O
drug	O
that	O
combines	O
tegafur	O
,	O
a	O
prodrug	O
of	O
5-FU	O
,	O
with	O
gimeracil	O
and	O
potassium	O
oxonate	O
in	O
a	O
molar	O
ratio	O
of	O
1:0.4:1	O
[	O
10,11	O
]	O
.	O
We	O
previously	O
performed	O
a	O
combination	O
chemotherapy	O
with	O
oral	O
S-1	O
and	O
biweekly	O
24-h	O
infusions	O
of	O
irinotecan	O
plus	O
bevacizumab	O
in	O
patients	O
with	O
mCRC	O
and	O
showed	O
that	O
this	O
regimen	O
appears	O
to	O
be	O
highly	O
active	O
and	O
well	O
tolerated	O
both	O
as	O
firstline	O
and	O
second	O
-	O
line	O
chemotherapy	O
for	O
mCRC	O
[	O
12,13	O
]	O
.	O

In	O
this	O
open	B-study_type
-	I-study_type
label	I-study_type
randomized	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
,	O
we	O
compared	O
combination	O
treatment	O
consisting	O
of	O
oral	O
S-1	O
and	O
a	O
24-h	O
infusion	O
of	O
irinotecan	O
plus	O
bevacizumab	B-arm_description
with	O
conventional	O
FOLFIRI	B-arm_description
plus	O
bevacizumab	B-arm_description
as	O
first	O
-	O
line	O
chemotherapy	O
for	O
mCRC	O
.	O

The	O
main	O
inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
histologically	O
confirmed	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
,	O
unresectable	O
or	O
recurrent	O
CRC	O
with	O
measurable	O
or	O
evaluable	O
disease	O
,	O
UGT1A1	O
*	O
28	O
genotype	O
(	O
6/6	O
or	O
6/7	O
)	O
,	O
an	O
age	O
of	O
20	O
years	O
or	O
older	O
,	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
(	O
ECOG	O
PS	O
)	O
of	O
0	O
or	O
1	O
,	O
a	O
life	O
expectancy	O
of	O
at	O
least	O
3	O
months	O
,	O
adequate	O
organ	O
function	O
,	O
and	O
no	O
previous	O
chemotherapy	O
or	O
prior	O
adjuvant	O
chemotherapy	O
for	O
CRC	O
with	O
-	O
in	O
3	O
months	O
before	O
enrollment	O
.	O
The	O
main	O
exclusion	O
criteria	O
were	O
as	O
follows	O
:	O
active	O
infection	O
,	O
bowel	O
obstruction	O
,	O
interstitial	O
pneumonia	O
and	O
pulmonary	O
fibrosis	O
,	O
uncontrolled	O
diabetes	O
,	O
pleural	O
effusion	O
or	O
ascites	O
,	O
pregnancy	O
and	O
lactation	O
,	O
and	O
known	O
drug	O
allergies	O
.	O
Patients	O
with	O
metastasis	O
or	O
recurrence	O
only	O
in	O
the	O
liver	O
were	O
excluded	O
because	O
they	O
were	O
enrolled	O
in	O
clinical	O
trials	O
of	O
other	O
regimens	O
,	O
including	O
hepatic	O
artery	O
infusion	O
.	O

This	O
trial	O
was	O
a	O
two	B-study_type
-	I-study_type
group	I-study_type
,	I-study_type
open	I-study_type
-	I-study_type
label	I-study_type
,	I-study_type
randomized	I-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
conducted	O
at	O
Tokai	O
University	O
Hospital	O
.	O
Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
oral	O
S-1	O
with	O
a	O
24-h	O
infusion	O
of	O
irinotecan	O
plus	O
bevacizumab	B-arm_description
(	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
)	O
or	O
FOLFIRI	B-arm_description
plus	O
bevacizumab	B-arm_description
(	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
)	O
.	O
Randomization	O
was	O
carried	O
out	O
centrally	O
,	O
with	O
minimization	O
stratified	O
by	O
the	O
number	O
of	O
metastatic	O
sites	O
(	O
1/≥2	O
)	O
,	O
the	O
primary	O
lesion	O
(	O
colon	O
/	O
rectum	O
)	O
,	O
the	O
primary	O
site	O
(	O
absent	O
/	O
present	O
)	O
,	O
and	O
ECOG	O
PS	O
(	O
0/1	O
)	O
.	O

The	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
regimen	O
comprised	O
irinotecan	O
(	O
125	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
given	O
as	O
a	O
24-h	B-arm_dosage
intravenous	I-arm_dosage
infusion	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
,	O
S-1	O
(	O
80	B-arm_dosage
mg/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
given	B-arm_dosage
orally	I-arm_dosage
in	I-arm_dosage
two	I-arm_dosage
divided	I-arm_dosage
daily	I-arm_dosage
doses	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
14	I-arm_dosage
,	O
and	O
bevacizumab	B-arm_description
(	O
5.0	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
)	O
,	O
given	O
as	O
an	O
intravenous	O
infusion	O
on	B-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
of	I-arm_dosage
each	I-arm_dosage
4-week	I-arm_dosage
cycle	I-arm_dosage
.	O
The	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
regimen	O
comprised	O
irinotecan	B-arm_description
(	O
150	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
given	O
as	O
a	O
90-min	B-arm_dosage
intravenous	I-arm_dosage
infusion	I-arm_dosage
,	O
and	O
l	B-arm_description
-	I-arm_description
leucovorin	I-arm_description
(	O
200	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
given	B-arm_dosage
as	I-arm_dosage
a	I-arm_dosage
120-min	I-arm_dosage
intravenous	I-arm_dosage
infusion	I-arm_dosage
,	O
an	O
intravenous	O
bolus	O
5-FU	B-arm_description
(	O
400	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
a	O
46-h	B-arm_dosage
continuous	I-arm_dosage
intravenous	I-arm_dosage
infusion	I-arm_dosage
of	O
5-FU	B-arm_description
(	O
2,400	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
and	O
bevacizumab	B-arm_description
(	O
5.0	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
)	O
,	O
given	O
as	O
an	B-arm_dosage
intravenous	B-arm_dosage
infusion	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
of	I-arm_dosage
each	I-arm_dosage
2-week	I-arm_dosage
cycle	I-arm_dosage
.	O

Immediately	O
before	O
the	O
infusion	O
of	O
irinotecan	O
,	O
the	O
patients	O
were	O
confirmed	O
to	O
have	O
a	O
leukocyte	O
count	O
of	O
≥3,000	O
/	O
μL	O
,	O
a	O
neutrophil	O
count	O
of	O
≥1,500	O
/	O
μL	O
,	O
and	O
a	O
platelet	O
count	O
of	O
≥100,000	O
/	O
μL	O
,	O
and	O
to	O
be	O
free	O
of	O
diarrhea	O
,	O
infection	O
,	O
or	O
fever	O
suggestive	O
of	O
infection	O
(	O
≥38	O
°	O
C	O
)	O
,	O
grade	O
1	O
or	O
lower	O
levels	O
of	O
serum	O
total	O
bilirubin	O
,	O
serum	O
aspartate	O
aminotransferase	O
,	O
and	O
alanine	O
aminotransferase	O
,	O
and	O
grade	O
2	O
or	O
lower	O
other	O
non	O
-	O
hematologic	O
toxicities	O
.	O

Bevacizumab	B-arm_description
was	O
given	O
to	O
patients	O
who	O
had	O
grade	O
2	O
or	O
lower	O
hypertension	O
,	O
proteinuria	O
(	O
protein	O
≤1	O
+	O
or	O
<	O
2	O
g	O
of	O
protein	O
per	O
24-h	O
urine	O
collection	O
)	O
,	O
and	O
grade	O
1	O
or	O
lower	O
bleeding	O
,	O
with	O
no	O
evidence	O
of	O
thrombosis	O
or	O
embolism	O
.	O
Treatment	O
was	O
discontinued	O
in	O
patients	O
who	O
had	O
any	O
of	O
the	O
following	O
conditions	O
:	O
gastrointestinal	O
perforation	O
,	O
grade	O
3	O
or	O
higher	O
hypertension	O
,	O
bleeding	O
,	O
thrombosis	O
or	O
embolism	O
,	O
hypersensitivity	O
,	O
and	O
grade	O
4	O
or	O
higher	O
proteinuria	O
.	O
Treatment	O
was	O
delayed	O
for	O
up	O
to	O
1	O
week	O
if	O
any	O
of	O
these	O
requirements	O
was	O
not	O
satisfied	O
.	O

In	O
patients	O
who	O
had	O
hematologic	O
toxicity	O
(	O
leukocyte	O
count	O
<	O
2,000	O
/	O
μL	O
,	O
neutrophil	O
count	O
<	O
1,000	O
/	O
μL	O
,	O
platelet	O
count	O
<	O
75,000	O
/	O
μL	O
,	O
or	O
serum	O
total	O
bilirubin	O
level	O
≥2.5	O
mg	O
/	O
dL	O
)	O
or	O
grade	O
3	O
or	O
higher	O
severe	O
non	O
-	O
hematologic	O
toxicities	O
,	O
the	O
doses	O
of	O
FU	O
,	O
S-1	O
,	O
and	O
irinotecan	O
were	O
decreased	O
by	O
20	O
%	O
.	O
If	O
treatment	O
could	O
not	O
be	O
resumed	O
within	O
28	O
days	O
after	O
withdrawal	O
,	O
treatment	O
was	O
discontinued	O
.	O

Pretreatment	O
evaluation	O
included	O
a	O
clinical	O
history	O
and	O
physical	O
examination	O
,	O
complete	O
blood	O
cell	O
count	O
,	O
blood	O
chemistry	O
,	O
urinalysis	O
,	O
electrocardiography	O
,	O
chest	O
radiography	O
,	O
and	O
CT	O
of	O
the	O
chest	O
and	O
abdomen	O
.	O
During	O
therapy	O
,	O
toxicity	O
was	O
assessed	O
weekly	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
-Common	O
Toxicity	O
Criteria	O
(	O
NCI	O
-	O
CTC	O
)	O
,	O
version	O
4.0	O
.	O
Physical	O
examination	O
was	O
conducted	O
,	O
and	O
the	O
results	O
were	O
recorded	O
before	O
each	O
cycle	O
,	O
or	O
more	O
frequently	O
if	O
clinically	O
indicated	O
.	O
Tumor	O
response	O
was	O
assessed	O
by	O
CT	O
scans	O
every	O
4	O
weeks	O
.	O
Efficacy	O
was	O
evaluated	O
after	O
every	O
cycle	O
according	O
to	O
the	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
,	O
version	O
1.1	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
1-year	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
rate	O
.	O
Secondary	O
endpoints	O
were	O
PFS	B-arm_efficacy_metric
,	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
adverse	O
events	O
.	O
The	O
primary	O
analysis	O
was	O
performed	O
in	O
the	O
full	O
analysis	O
set	O
.	O
Safety	O
analyses	O
were	O
performed	O
in	O
patients	O
who	O
had	O
received	O
the	O
protocol	O
treatment	O
at	O
least	O
once	O
.	O

Assuming	O
that	O
the	O
lower	O
threshold	O
of	O
the	O
1-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
30	B-arm_efficacy_results
%	I-arm_efficacy_results
in	O
patients	O
who	O
had	O
not	O
previously	O
received	O
chemotherapy	O
and	O
that	O
the	O
expected	O
1-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
70	B-arm_efficacy_results
%	I-arm_efficacy_results
,	O
with	O
a	O
one	O
-	O
side	O
α	O
value	O
of	O
0.05	O
and	O
a	O
β	O
value	O
of	O
0.2	O
,	O
we	O
calculated	O
the	O
target	O
number	O
of	O
previously	O
untreated	O
patients	O
to	O
be	O
46	O
in	O
each	O
groups	O
.	O
The	O
target	O
number	O
of	O
patients	O
was	O
therefore	O
set	O
at	O
100	O
,	O
including	O
dropouts	O
and	O
excluded	O
patients	O
.	O

Time	O
-	O
dependent	O
events	O
were	O
analyzed	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
A	O
log	O
-	O
rank	O
test	O
was	O
used	O
to	O
compare	O
the	O
survival	O
rates	O
between	O
the	O
groups	O
.	O
Fisher	O
's	O
test	O
was	O
used	O
to	O
compare	O
treatment	O
responses	O
between	O
the	O
groups	O
.	O

From	O
December	O
2013	O
through	O
January	O
2018	O
,	O
a	O
total	O
of	O
120	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
regimen	I-arm_description
(	O
n	O
=	O
61	O
)	O
or	O
to	O
a	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
regimen	I-arm_description
(	O
n	O
=	O
59	O
)	O
.	O
Overall	O
,	O
22	O
patients	O
(	O
10	O
patients	O
in	O
the	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
and	O
12	O
patients	O
in	O
the	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
)	O
were	O
not	O
treated	O
after	O
randomization	O
because	O
of	O
the	O
patients	O
'	O
request	O
(	O
n	O
=	O
7	O
)	O
,	O
ileus	O
(	O
n	O
=	O
3	O
)	O
,	O
jaundice	O
(	O
n	O
=	O
3	O
)	O
,	O
aggravation	O
of	O
general	O
condition	O
(	O
n	O
=	O
3	O
)	O
,	O
pneumonia	O
(	O
n	O
=	O
2	O
)	O
,	O
the	O
presence	O
of	O
cancer	O
in	O
organs	O
other	O
than	O
the	O
col	O
-	O
orectum	O
(	O
n	O
=	O
2	O
)	O
,	O
perforation	O
(	O
n	O
=	O
1	O
)	O
,	O
or	O
heart	O
failure	O
(	O
n	O
=	O
1	O
)	O
.	O

The	O
full	O
analysis	O
set	O
population	O
comprised	O
98	O
patients	O
(	O
51	O
patients	O
in	O
the	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
arm	I-arm_description
and	O
47	O
patients	O
in	O
the	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
arm	I-arm_description
)	O
.	O
The	O
cut	O
-	O
off	O
date	O
for	O
primary	O
analysis	O
of	O
the	O
primary	O
endpoint	O
was	O
November	O
2018	O
.	O
Patient	O
characteristics	O
were	O
similar	O
in	O
both	O
groups	O
(	O
Table	O
1	O
)	O
.	O
Two	O
weeks	O
of	O
treatment	O
was	O
counted	O
as	O
one	O
cycle	O
in	O
both	O
groups	O
.	O
The	O
median	O
number	O
of	O
treatment	O
cycles	O
was	O
17	O
(	O
range	O
4	O
-	O
58	O
)	O
in	O
the	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
and	O
15	O
(	O
range	O
2	O
-	O
44	O
)	O
in	O
the	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
.	O

The	O
median	O
follow	O
-	O
up	O
period	O
was	O
22.8	O
months	O
(	O
range	O
3.1	O
-	O
58.8	O
)	O
.	O
The	O
1-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
,	O
the	O
primary	O
endpoint	O
,	O
was	O
43.14	B-arm_efficacy_results
%	I-arm_efficacy_results
in	O
the	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
and	O
19.15	B-arm_efficacy_results
%	I-arm_efficacy_results
in	O
the	O
FOLFIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
=	I-arm_efficacy_results
0.312	I-arm_efficacy_results
[	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
0.13	I-arm_efficacy_results
-	I-arm_efficacy_results
0.78	I-arm_efficacy_results
]	I-arm_efficacy_results
,	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.01	I-arm_efficacy_results
;	I-arm_efficacy_results
Fig	I-arm_efficacy_results
.	I-arm_efficacy_results
1	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O
The	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
10.2	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
8.8	I-arm_efficacy_results
-	I-arm_efficacy_results
14.3	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
10.0	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
7.4	I-arm_efficacy_results
-	I-arm_efficacy_results
11.0	I-arm_efficacy_results
)	I-arm_efficacy_results
,	O
respectively	O
(	B-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.375	I-arm_efficacy_results
;	I-arm_efficacy_results
Fig	I-arm_efficacy_results
.	I-arm_efficacy_results
1	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O
The	O
median	O
OS	O
was	O
29.7	O
months	O
(	O
95	O
%	O
CI	O
22.9	O
-	O
43.9	O
)	O
,	O
and	O
28.8	O
months	O
(	O
95	O
%	O
CI	O
18.4	O
to	O
ND	O
)	O
,	O
respectively	O
(	O
p	O
=	O
0.823	O
;	O
Fig	O
.	O
2	O
)	O
.	O
The	O
ORR	O
was	O
86.3	O
Values	O
are	O
given	O
as	O
n	O
unless	O
indicated	O
otherwise	O
.	O
and	O
61.7	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.0053	O
;	O
Table	O
2	O
)	O
.	O
Complete	O
responses	O
were	O
obtained	O
in	O
8	O
patients	O
(	O
15.7	O
%	O
)	O
and	O
3	O
patients	O
(	O
6.4	O
%	O
)	O
,	O
respectively	O
.	O
Adverse	O
events	O
are	O
summarized	O
in	O
Table	O
3	O
.	O
The	O
incidence	O
rates	O
of	O
grade	O
3	O
or	O
higher	O
hematologic	O
toxicities	O
were	O
similar	O
.	O
The	O
incidence	O
rates	O
of	O
grade	O
3	O
or	O
higher	O
gastrointestinal	O
toxicities	O
,	O
such	O
as	O
diarrhea	O
,	O
anorexia	O
,	O
and	O
nausea	O
,	O
were	O
higher	O
in	O
the	O
24h	O
-	O
SIRI	B-arm_description
/	I-arm_description
B	I-arm_description
group	I-arm_description
.	O